Tripeptide, copper-free form of GHK-cu
GHK (Tripeptide-1)
GHK (Tripeptide-1) after one dose: 50% at ~4 h, 25% at 8 h, 12.5% at 12 h.
Drawn from the half-life in the app's model, ~4 h. The model's figures
- Compound
- GHK (Tripeptide-1)
- Symbol
- GH3
- Family
- Cosmetic and copper peptides
- Parts
- 12
- References
- 12
- Checked
- Last reviewed . Sources are listed below.
Overview
GHK (glycyl-L-histidyl-L-lysine) is a three-amino-acid peptide that Pickart and colleagues (BioMed Research International, 2015) describe as present in human plasma, saliva and urine and declining with age.3 Copper-free GHK, also called apo-GHK, is the peptide without deliberate copper complexation, and GHK-Cu is the copper(II) complex of the same peptide.2 Mateescu and colleagues (Pharmaceutics, 2026) write that "Apo-GHK, canonical GHK-Cu, GHK-derived copper peptides, and unrelated copper-peptide systems cannot be treated as interchangeable", so each result below states which form was tested.2 The same 2015 review writes: "It is proposed that GHK functions as a complex with copper 2+ which accelerates wound healing and skin repair".3 Choi and colleagues (Journal of Peptide Science, 2012) write that "In industry, GHK (with or without copper) is used to make hair and skin care products".4 The app files GHK (Tripeptide-1) as a tripeptide in its healing peptide category, lists the routes SubQ and topical, and grades the evidence emerging. The app's notes give Tripeptide-1 as the INCI name of the copper-free form and say it is used in topical skincare and subcutaneously. For the copper complex, the 2026 evidence-mapping review describes GHK-Cu as a "promising but unproven therapeutic cargo rather than a clinically validated regenerative drug".2 Mendias and Awan (Sports Medicine, 2026), of the Performance Medicine Institute in Phoenix, list GHK-Cu among the peptides covered in a narrative review of approved and unapproved peptide therapies.5 Their general statement, about unapproved peptides as a group and not about GHK alone, is that "Many unapproved peptides demonstrate favorable tissue repair and metabolic outcomes in animal models, but rigorous human safety data are scarce, and there is potential for serious harm to patients".5 Their disclosure says that "Tariq M. Awan receives consulting fees from Arthrex for activities unrelated to topics discussed in this article."5
How it works
Choi and colleagues describe GHK as "a naturally occurring copper(II)-chelating motifs in human serum and cerebrospinal fluid".4 They add that "the effects of copper-free GHK (GHK) have not been investigated well".4 In cultured human keratinocytes and skin-equivalent models, the same group reports that GHK increased keratinocyte proliferation and integrin expression, which they link to the "stemness and proliferative potential of epidermal basal cells".4 In bleomycin-treated mice, Zhou and colleagues (Frontiers in Pharmacology, 2017) report that "GHK reversed BLM-induced increases in TGF-β1, p-Smad2, p-Smad-3 and insulin-like growth factor-1 (IGF-1) expression".6 In normal human dermal fibroblasts, Gruchlik and colleagues (Acta Poloniae Pharmaceutica, 2014) report that "GHK and its copper complex and free copper ions decreased IGF-2-dependent TGF-β1 secretion".7 In that experiment GHK, GHK-Cu and CuCl2 were each tested at 1 nM and each decreased IGF-2-dependent TGF-β1 secretion, so a decrease was reported with the peptide, with its copper complex and with free copper ions.7 A 2012 paper from the same group says of the anti-inflammatory properties of these peptides that "The mechanism of anti-inflammatory properties of these peptides is not clear".8 The 2026 evidence-mapping review sorts mechanisms into three classes, and places "connectivity-map signature reversal obtained largely with apo-GHK in silico" in the third, "systems-level claims that are hypothesis-generating only".2 It adds that these claims, "none of which establishes tissue exposure or a validated human target".2
Half-life and pharmacokinetics
Values from the Milligram app's model.
- Half-life
- ~4 h
- Bioavailability
- 95%
- Typical dose
- 1–3 mg/day
- Route
- SubQ, topical
- Time to peak
- ~0.5 h
The table sets the app's figures beside what the sources report; the rat data are for GHK itself, and the other entries are labelled by the form tested.
| Parameter | App's figure | Reported in the sources |
|---|---|---|
| Half-life | About 4 hours, one-compartment model | In rats after a single intravenous dose, "GHK was rapidly degraded to HK, which was eliminated rapidly" (Endo and colleagues, Kissei Pharmaceutical, 1997); the 1997 record gives no half-life value. A 2026 review writes that "free GHK is therefore expected to have a short systemic half-life"1,2 |
| Bioavailability | 95% | None of the sources read gives a bioavailability figure for GHK in people. For skin, Hur and colleagues write that "The hydrophilic GHK and GHK-Cu are limited in their abilities to penetrate deeply into skin"9 |
| Time to peak and duration | About 0.5 h to peak; about 8 h duration | None of the sources read gives a time to peak or a duration for GHK |
| Breakdown route | Not given | Rat: GHK degraded to the metabolite L-histidyl-lysine (HK); review: proteolysis to "glycine, histidyl-lysine, and free amino acids" is expected to be the dominant route1,2 |
Among the sources read, none gives a numeric half-life for GHK, so the app's 4-hour figure has no figure from the sources beside it.1,2 Endo and colleagues, of the Pharmacological Laboratories of Kissei Pharmaceutical Co., Ltd., describe a method with a limit of detection of "50 and 15 ng/ml" for GHK and HK.1 The PubMed record for that paper gives no rat numbers, dose or funding statement, and it describes GHK as "a liver-cell growth factor isolated from human plasma".1 For the copper complex, Badenhorst and colleagues (University of Auckland, Pharmaceutical Development and Technology, 2016) report that distribution coefficients "indicated the highly hydrophilic nature of GHK-Cu with log D values between -2.38 and -2.49 at pH range of 4.5-7.4".10 The same group reports that GHK-Cu "was stable in water and in pH (4.5-7.4) buffers for at least two weeks at 60 °C" and was susceptible to hydrolytic cleavage under basic and oxidative stress, in laboratory conditions and not in the body.10 The 2026 evidence-mapping review says that "Formal absorption, distribution, metabolism, and excretion studies of the intact complex" have not been reported, a statement about GHK-Cu.2
Human studies
No controlled trial of copper-free GHK in people was identified in the first 20 of 40 PubMed records returned for "GHK tripeptide glycyl-histidyl-lysine", or among the studies ClinicalTrials.gov returned for "glycyl-histidyl-lysine OR GHK tripeptide". The two human entries below are reviews that do not isolate copper-free GHK; the studies on copper-free GHK itself are in cells, skin models, mice and rats and follow under Deeper analysis.
| Study and year | Design | People | Dose and length | Main result |
|---|---|---|---|---|
| Joerg and colleagues, Journal of Drugs in Dermatology 202611 | Systematic review of English-language clinical trials of peptide-containing therapies for hair loss; PubMed, Embase and Cochrane Library searched 3 November 202511 | 14 of 981 identified studies met the inclusion criteria; the number of participants and the number testing GHK are not given in the PubMed record11 | Dose and length not given in the PubMed record11 | Grade of recommendation B for formulations including "glycyl-histidyl-lysine peptide"; copper content and trial-level GHK results not stated11 |
| Mateescu and colleagues, Pharmaceutics 2026 (human GHK-Cu studies summarised)2 | Systematic evidence-mapping review, no quantitative pooling2 | GHK-Cu studies, not copper-free GHK; the review lists four human studies (1998, 2002, post-CO2-laser, eyebrow) and the two here are a randomized post-CO2-laser study in which 13 participants completed follow-up and a randomized double-blind split-face eyebrow study in 18 healthy participants2 | Eyebrow study: a nominal 2% GHK-Cu serum; no dose or length for the post-laser study in the review text read, and no length for the eyebrow study2 | 13-participant study "negative on objective endpoints" and called underpowered by the review; 18-participant study "positive cosmetic hair outcomes", called a small single-center study with a cosmetic endpoint and chemically undercharacterized test material, without a defined GHK-Cu form2 |
Deeper analysis: the 2026 systematic review of peptides for hair loss
Joerg and colleagues (Journal of Drugs in Dermatology, 2026) searched PubMed, Embase and the Cochrane Library on 3 November 2025 and found 14 of 981 studies eligible.11 They graded formulations containing "glycyl-histidyl-lysine peptide" B, and graded QR678 and QR678 Neo C.11 Their conclusion is that "Clinical data support peptide-based formulations, particularly combinations containing acetyl tetrapeptide-3, biotinoyl tripeptide-1, and glycyl-histidyl-lysine peptide as effective, well-tolerated alternatives to conventional hair-growth therapies".11 The PubMed record lists no author affiliations, funding statement or stated limitations, gives no trial-level GHK results, and does not say whether the GHK in the included formulations carried copper; the result cannot be read as a result for copper-free GHK.11
Deeper analysis: GHK in bleomycin-induced lung fibrosis in mice
Zhou and colleagues, from China Medical University hospitals in Shenyang, reported the study in Frontiers in Pharmacology in 2017; it was in mice and not in people.6 Design: "Fifty male C57BL/6 mice aged eight to 9 weeks and weighing 18–22 g were randomly divided into the following five experimental groups (n = 10 per group)": a normal control, a bleomycin (BLM) group and three BLM groups given GHK.6 Bleomycin was given once intratracheally at 3 mg/kg, and GHK was given intraperitoneally at 2.6, 26 and 260 μg/ml/day every other day from the 4th to the 21st day after bleomycin, with mice killed on day 21.6 The authors write that the doses "were based on data regarding the concentration of the drug in human plasma and the results of a previous study".6 Measured outcomes were lung histology (hematoxylin-eosin and Masson's trichrome staining), cytokines in bronchoalveolar lavage fluid, myeloperoxidase activity, collagen deposition and western blot markers of fibrosis and epithelial-mesenchymal transition.6 Results: "Treatment with GHK at all three doses reduced inflammatory cell infiltration and interstitial thickness and attenuated BLM-induced pulmonary fibrosis in mice".6 Further, "GHK treatment significantly improved collagen deposition, and MMP-9/TIMP-1 imbalances in lung tissue and also reduced TNF-α, IL-6 expression in bronchoalveolar lavage fluid (BALF) and MPO in lung extracts".6 On body weight, the results text reports that "the weight loss and the increase in the W/D weight ratio caused by BLM instillation were remarkably reversed by GHK treatment".6 The results are given in words and figures, analysed by one-way ANOVA, with data shown as mean ± SEM; the text read does not report deaths or other adverse events in the mice.6 The authors' stated limitations: "We did not block IGF-1 to confirm our findings, we did not compare the difference in efficacy between GHK and GHK-Cu".6 They add that "the dose-response curve has not been covered in our study".6 The methods name the compound GHK and give no copper content for it; copper and GHK-Cu are mentioned only in the discussion.6 Funding: "This research was supported by grant 2014225006 from Department of Science and Technology of Liaoning Province, China, grant LT2013015 from Department of Education of Liaoning Province, China, and grant F13-316-1-72 from Science and Technology Bureau of Shenyang, China".6 The authors declare "the absence of any commercial or financial relationships that could be construed as a potential conflict of interest".6 Their conclusion is that "GHK may thus be a candidate for the treatment of pulmonary fibrosis", a statement about a mouse model.6
Deeper analysis: copper-free GHK in keratinocytes and skin-equivalent models
Choi and colleagues, of the Department of Dermatology, Seoul National University Bundang Hospital, published the study in the Journal of Peptide Science in 2012.4 Design: "the effects of GHK were studied using cultured normal human keratinocytes and skin equivalent (SE) models".4 In the skin-equivalent models, "the basal cells became more cuboidal than control model", with "linear and intense staining of α6 and β1 integrin along the basement membrane".4 "The number of p63 and proliferating cell nuclear antigen positive cells was also significantly increased in GHK-treated SEs than in control SEs".4 The authors conclude that "copper-free GHK showed similar effects with copper-GHK" and that "Further study is necessary to explore the relationship between copper-free GHK and copper-GHK".4 They also write that copper-free GHK "can be used in industry to obtain the effects of copper-GHK in vivo", a conclusion drawn from cell and skin-model experiments.4 The PubMed record lists the publication type "Research Support, Non-U.S. Gov't" but gives no funder name, no conflict-of-interest statement, no GHK concentration, no number of replicates and no stated limitations beyond the call for further study.4
Deeper analysis: fibroblast studies of GHK, GHK-Cu and copper
Gruchlik and colleagues (Acta Poloniae Pharmaceutica, 2014) tested "1 nM solutions of GHK, GHK-Cu and CuCl2" in normal human dermal fibroblasts, with TGF-β1 measured by ELISA.7 IGF-2 at 100 ng/mL "resulted in a significant increase in TGF-β1 secretion", and GHK, its copper complex and free copper ions each decreased it.7 The authors, who list no funder in the PubMed record (publication type "Research Support, Non-U.S. Gov't"), draw a link to "potential use of that peptide contained in cosmetics" in hypertrophic scars, a use not tested in people in the study.7 A 2012 study by Gruchlik and colleagues of the Department of Biopharmacy, Medical University of Silesia, tested GGH, GHK, CuCl2 and their copper complexes, and reports that all "decreased TNF-alpha-dependent IL-6 secretion in fibroblasts".8 Neither PubMed record gives concentrations beyond the 1 nM in the 2014 study, numbers of replicates or stated limitations.7,8
Deeper analysis: the 2026 evidence-mapping review
Mateescu and colleagues searched "PubMed/MEDLINE, Europe PMC, major publisher platforms, ClinicalTrials.gov, backward citation chains, and official European Union, U.S., and ICH regulatory sources from database inception through 12 August 2026".2 They conclude that "the clinical evidence remains sparse and does not meet contemporary active-entity quality standards".2 For the registered phase 2 wound study NCT07437586, they write that it "remains recruiting and has no efficacy results" and that its registration "cannot be interpreted as evidence of clinical efficacy or successful clinical translation".2 That study concerns GHK-Cu, and the review's funding is not stated in the text read; its conflict statement reads "The authors declare no conflicts of interest."2
Doses reported in studies and on labels
Sources in this part
No drug label for copper-free GHK was identified in DailyMed, and none of the studies read reports a dose of copper-free GHK in people.
| Dose or concentration | Setting, comparator, duration, n | Reference |
|---|---|---|
| 1 to 3 mg/day by SubQ or topical routes | The app's typical dose range; the sources read give no study or label behind it | The app |
| 2.6, 26 and 260 μg/ml/day, intraperitoneal, every other day | Male C57BL/6 mice, n = 10 per group, bleomycin 3 mg/kg intratracheal versus saline control and bleomycin alone; days 4 to 21 after bleomycin6 | Zhou 20176 |
| 1 nM GHK (also GHK-Cu and CuCl2 in separate wells) | Normal human dermal fibroblasts in 24-well plates with 100 ng/mL IGF-2; n not stated in the PubMed record7 | Gruchlik 20147 |
| A single intravenous dose, amount not stated in the PubMed record | Rats, one dose, plasma GHK and HK measured; n not stated in the PubMed record1 | Endo 19971 |
Side effects reported
None of the sources read reports human safety data for copper-free GHK. Two fibroblast papers describe tripeptides such as GHK and their copper complexes as having "a high activity and good skin tolerance", a statement in their introductions and not a measured result.7,8 Joerg and colleagues describe peptide-based formulations containing glycyl-histidyl-lysine peptide as "well-tolerated", without a tolerability result for GHK in the PubMed record.11 Zhou and colleagues write in their discussion that "GHK is naturally occurring, non-toxic, and readily forms complexes with copper", an assertion in a mouse paper that did not test toxicity.6 Mendias and Awan write about unapproved peptides in general that "rigorous human safety data are scarce".5 The 2026 evidence-mapping review states that "Where injectable copper-peptide preparations are supplied outside an approved marketing authorization, they sit outside any defined evidentiary or quality framework", a statement about copper-peptide preparations.2
Regulatory and anti-doping status
Sources in this part
The WADA 2026 Prohibited List does not name GHK or tripeptide in the text read.12 Its class S0 covers "Any pharmacological substance which is not addressed by any of the subsequent sections of the List and with no current approval by any governmental regulatory health authority for human therapeutic use".12 The list names BPC-157 as an example in S0 and says the class covers "many different substances including but not limited to" its examples.12 None of the sources read states whether GHK falls under S0, and the question is left open here. No regulator label or marketing approval for copper-free GHK was identified in DailyMed or in the sources read. The 2026 evidence-mapping review says that the rules on "compounded and unapproved peptide preparations differ substantially between jurisdictions and change frequently".2
What is not known
Sources in this part
- It is not established whether copper-free GHK and GHK-Cu act alike: Choi and colleagues call for "Further study" on the relationship, and the 2026 review keeps them as separate evidence classes.4,2
- Among the sources read, none reports a measured half-life, bioavailability or time to peak of GHK in people, so the app's figures have no figures from the sources beside them.
- The 2026 review says of the "Pulmonary, neurological and systemic" evidence that it mixes apo-GHK computational work with GHK-Cu animal studies, with "no human exposure data".2
- No controlled trial of copper-free GHK in people was identified in the PubMed and ClinicalTrials.gov queries described above; the copper content of the GHK in the hair-loss formulations reviewed by Joerg and colleagues is not stated, so the human record for copper-free GHK specifically is not established.11
Frequently asked questions
What does Tripeptide-1 mean?
Tripeptide-1 is the INCI name the app's notes give for the copper-free form of glycyl-L-histidyl-L-lysine.
Is GHK approved as a drug?
No label or marketing approval for copper-free GHK was identified in DailyMed or in the sources read. For the copper complex, the 2026 review calls GHK-Cu a "promising but unproven therapeutic cargo rather than a clinically validated regenerative drug".2
Does GHK penetrate the skin?
Hur and colleagues write that "The hydrophilic GHK and GHK-Cu are limited in their abilities to penetrate deeply into skin".9 That paper compared GHK with an oligoarginine conjugate, GHK-R4, in vitro and in vivo, and two authors are listed at Dermafirm Co., Ltd. The record lists grants from Soonchunhyang University and the National Research Foundation of Korea.9
What do animal studies show for GHK?
In mice given bleomycin, GHK at 2.6, 26 and 260 μg/ml/day reduced inflammatory cell infiltration and attenuated lung fibrosis in a 2017 study of 50 mice.6 The authors list as limitations that they did not block IGF-1 to confirm their findings, did not compare GHK with GHK-Cu and did not cover a dose-response curve.6
More in Cosmetic and copper peptides
References
- Endo T, Miyagi M, Ujiie A. Simultaneous determination of glycyl-L-histidyl-L-lysine and its metabolite, L-histidyl-L-lysine, in rat plasma by high-performance liquid chromatography with post-column derivatization. J Chromatogr B Biomed Sci Appl 1997. PMID 9187381
- Mateescu DM, et al. GHK-Cu as a Bioactive Metallopeptide and Drug-Delivery Cargo: Coordination Chemistry, Formulation Science, Therapeutic Evidence, and a Translational Roadmap. Pharmaceutics 2026. PMC13610439
- Pickart L, Vasquez-Soltero JM, Margolina A. GHK Peptide as a Natural Modulator of Multiple Cellular Pathways in Skin Regeneration. Biomed Res Int 2015. PMID 26236730
- Choi HR, et al. Stem cell recovering effect of copper-free GHK in skin. J Pept Sci 2012. PMID 23019153
- Mendias CL, Awan TM. Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance. Sports Med 2026. PMID 41966639
- Zhou XM, et al. GHK Peptide Inhibits Bleomycin-Induced Pulmonary Fibrosis in Mice by Suppressing TGFβ1/Smad-Mediated Epithelial-to-Mesenchymal Transition. Front Pharmacol 2017. PMID 29311918
- Gruchlik A, Chodurek E, Dzierzewicz Z. Effect of GLY-HIS-LYS and its copper complex on TGF-β secretion in normal human dermal fibroblasts. Acta Pol Pharm 2014. PMID 25745767
- Gruchlik A, Jurzak M, Chodurek E, Dzierzewicz Z. Effect of Gly-Gly-His, Gly-His-Lys and their copper complexes on TNF-alpha-dependent IL-6 secretion in normal human dermal fibroblasts. Acta Pol Pharm 2012. PMID 23285694
- Hur GH, et al. Effect of oligoarginine conjugation on the antiwrinkle activity and transdermal delivery of GHK peptide. J Pept Sci 2020. PMID 31788907
- Badenhorst T, Svirskis D, Wu Z. Physicochemical characterization of native glycyl-l-histidyl-l-lysine tripeptide for wound healing and anti-aging: a preformulation study for dermal delivery. Pharm Dev Technol 2016. PMID 25384620
- Joerg L, Zafar K, Jagdeo J. Peptides for Hair Growth and Treatment of Hair Loss and Alopecia: A Systematic Review. J Drugs Dermatol 2026. PMID 42976838
- World Anti-Doping Agency. World Anti-Doping Code International Standard: Prohibited List 2026. WADA list